Neohesperidin dihydrochalcone
| Common Name: |
Neohesperidin dihydrochalcone |
| IUPAC Name: |
1-[4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)propan-1-one |
| Molecular Formula: |
C28H36O15 |
| SMILES: |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C(C(=C3)O)C(=O)CCC4=CC(=C(C=C4)OC)O)O)CO)O)O)O)O)O |
| Inchi: |
1S/C28H36O15/c1-11-21(34)23(36)25(38)27(40-11)43-26-24(37)22(35)19(10-29)42-28(26)41-13-8-16(32)20(17(33)9-13)14(30)5-3-12-4-6-18(39-2)15(31)7-12/h4,6-9,11,19,21-29,31-38H,3,5,10H2,1-2H3/t11-,19+,21-,22+,23+,24-,25+,26+,27-,28+/m0/s1 |
| Inchi Key: |
ITVGXXMINPYUHD-CUVHLRMHSA-N |
| Cas No: |
20702-77-6 |
| Name |
Value |
| Lipinski Violations |
3 |
| Ghose Violations |
4 |
| Veber Violations |
1 |
| Egan Violations |
1 |
| Muegge Violations |
4 |
| Name |
Value |
| Molecular Weight (g/mol) |
612.58 |
| Mass (g/mol) |
612.205 |
| Molar Refractivity |
143.86 |
| Net Charge |
|
| HBD |
9 |
| HBA |
15 |
| Rt Bonds |
10 |
| Rings |
4 |
| TPSA |
245.29 |
| Hetero Atoms |
15 |
| Heavy Atoms |
43 |
| Aromatic Heavy Atoms |
12 |
| Melting Point (°C) |
156.00 to 158.00 |
| Boiling Point (°C@760.00mm Hg) |
927.13 |
| Vapor Pressure (mmHg@25.00 °C) |
|
| Vapor Density (Air =1) |
|
| Fraction Csp3 |
0.54 |
| LogP |
-1.342 |
| iLOGP |
2.63 |
| XLOGP3 |
-0.30 |
| WLOGP |
-1.34 |
| MLOGP |
-3.04 |
| ESOL Log S |
-3.00 |
| ESOL Solubility (mg/ml) |
0.619 |
| ESOL Solubility (mol/l) |
0.001 |
| ESOL Class: esol_class |
Soluble |
| Ali Log S |
-4.39 |
| Ali Solubility (mg/ml) |
0.02 |
| Ali Solubility (mol/l) |
0 |
| Ali Class |
Moderately soluble |
| Silicos-IT LogSw |
-0.53 |
| Silicos-IT Solubility (mg/ml) |
180 |
| Silicos-IT Solubility (mol/l) |
0.29 |
| Silicos-IT Class |
Soluble |
| Name |
Value |
| GI Absorption |
Low |
| BBB Permeable |
0 |
| PgP Substrate |
1 |
| Log Kp (cm/s) |
-10.25 |
| Bioavailability Score |
0.17 |
| Caco2 |
0 |
| Human Intestinal Absorption |
1 |
| Plasm Protein Binding |
0.8 |
| CYP1A2 Inhibitor |
0 |
| CYP2C19 Inhibitor |
0 |
| CYP2C9 Inhibitor |
0 |
| CYP2D6 inhibitor |
0 |
| CYP3A4 inhibitor |
0 |
| Ames mutagenesis |
0 |
| Acute Oral Toxicity |
2.378 |
| Carcinogenicity (Binary) |
0 |
| Carcinogenicity (Trinary) |
Non-required |
| Eye Irritation |
0 |
| Hepatotoxicity |
1 |
| Androgen Receptor Binding |
0 |
| Aromatase Binding |
1 |
| Estrogen Receptor Binding |
1 |
| Glucocorticoid Receptor Binding |
0 |
| Thyroid Receptor Binding |
1 |
| BRCP inhibitor |
0 |
| BSEP inhibitor |
1 |
| OATP1B1 inhibitor |
1 |
| OATP1B3 inhibitor |
1 |
| OATP2B1 inhibitor |
0 |
| OCT1 inhibitor |
0 |
| OCT2 inhibitor |
0 |
